Brookline Capital Markets initiated coverage of Medicus Pharma (MDCX) with a buy rating, citing the potential of its basal ...

Medicus Pharma Ltd (MDCX) has received a new Buy rating, initiated by Brookline Capital Markets analyst, Kumaraguru Raja.Don't Miss Our ...

Brookline analyst Kumaraguru Raja initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $12 price target Medicus is advancing ...

Brookline analyst Kumaraguru Raja initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $12 price target Medicus is advancing D-MNA, a doxorubicin tip loaded dissolvable microarray ...

Tuesday, Brookline Capital Markets initiated coverage on Medicus Pharma Ltd. (NASDAQ:MDCX) with a Buy rating and a price target of $12.00. The firm's analyst cited the potential of the company's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tuesday, Brookline Capital Markets initiated coverage on Medicus Pharma Ltd. (NASDAQ:MDCX) with a Buy rating and a price target of $12.00. The firm's analyst cited the potential of the company's ...

Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in HorsesTORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ ...